台英帝國 Imperial Tobacco Taiwan Manufacturing Co., Ltd. - Qunyi Rd

Why it is important?

We recognise that consumer health is the most important ESG priority for many of our stakeholders and that we need to build a successful next generation product (NGP) business. Our commercial strategy, launched in 2021, announced our intention to challenge through NGP market trials. This has been a key pillar of our new business strategy, and our ESG strategy aims to complement this by bringing a focus to how we address consumer health by offering adult smokers a range of products that have the potential of harm reduction at population level.

A consumer-led harm reduction strategy

We start with the consumer, focusing on consumer insight and research to ensure we build a portfolio that suits them.

We substantiate the harm reduction potential of our NGP through our multi-stage, multi-year testing and research programme. This scientific assessment framework is applied for each NGP type compared to cigarettes to assess the relative risk. You can explore in more detail on our science website.

Based on our scientific research and market research, we will link the findings into our NGP innovation process in order to innovate for stronger consumer satisfaction and to drive harm reduction by enabling smokers to choose potentially less harmful products.

Download ESG strategy report for more information